In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other, and you, the reader, will determine the winner.
World Wrestling Entertainment takes on Isis Pharmaceuticals for this first round-robin match up in our search for the better stock today.
Consumer-goods analyst Mark Reeth believes World Wrestling Entertainment (NYSE:WWE) should win this matchup for one simple reason: fan loyalty. Wrestling fans pay big money for the big events, like Raw and Smackdown. What they don't usually do are pay for the other, lesser bouts sprinkled throughout the year. That means WWE needs to spruce up its events and keep things interesting enough that people come back for more than just the big once-a-year matches. With 670,000 people already subscribed to the WWE Network, once WWE inevitably hits 1 million subscribers and breaks even, everything beyond that goes to the bottom line and into investors' pockets.
David Williamson, The Motley Fool health-care analyst, thinks Isis Pharmaceuticals (NASDAQ:ISIS) should advance to the next round for one big reason -- its amazing drug pipeline. Wall Street heralds it as the best in biotech and puts Isis in play as a takeover target. A virtual who's who of big pharma has struck partnership deals. Isis already has orphan drug Kynamro on the market and has seen recent success from a mid-stage study for an anti-clotting drug. A recent sell-off has given investors a chance to get this deep pipeline at a discounted price.
Warren Buffett vs. his worst nightmare
Warren Buffett just called this emerging technology a "real threat" to his biggest cash cow. While Buffett shakes in his billionaire boots, only a few investors are embracing this new market, which experts say will be worth over $2 trillion. It won't be long before everyone on Wall Street wises up, and that's why The Motley Fool is releasing this timely investor alert. Click here to learn more about what's keeping Buffett up at night and the one public company we're calling the brains behind the technology.
Vote here to determine the winner of this match, and sound off in the comments. Check back to Fool.com to see who advances in the tournament.
David Williamson and Mark Reeth have no position in any stocks mentioned. The Motley Fool recommends Isis Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.